共查询到19条相似文献，搜索用时 140 毫秒
1.
对来源于鹿、牛和鼠的狂犬病病毒（RV）野毒株8202、BRV、MRV的G基因405～1 146位核苷酸序列进行了RT-PCR扩增、克隆和序列测定,并应用计算机软件对这3个毒株的测定序列和人源株CGX89的相应序列进行了分析比较。结果表明,这4个不同来源RV的G基因主要功能区的分子差异较大,4个野毒株的糖基化位点和主要诱导中和抗体产生的抗原决定簇内某些氨基酸亦不同,这些差异将影响它们的抗原性和毒性。研究结果证明,在我国流行的RV野毒株中存在亲缘关系较远的毒株,其野毒株G基因较大的分子差异可能影响疫苗的免疫保护效果。 相似文献
2.
为阐明狂犬病病毒（RV）不同毒力株感染鼠脑后基因表达的差异,进一步揭示RV感染和机体抗感染应答的分子机制。本试验应用差异显示技术分析了正常鼠脑悬液、狂犬病病毒SRV9弱毒株及BD06街毒株感染鼠脑48h的基因水平变化。结果显示,与对照组相比,SRV9与BD06组有4对共同上调表达差异片段;与其它两组比较,SRV9组有2个基因上调表达,BD06组存在1个上调表达基因。这些差异基因体现了宿主细胞对RV感染的应答模式以及不同毒株感染间的差异,为深入研究RV致病机理奠定了基础。 相似文献
3.
4.
根据Gen Bank中猪流行性腹泻病毒(PEDV)的基因序列分别设计两对引物,在完成最佳条件筛选、特异性、敏感性试验的基础上,建立一种快速区分PEDV疫苗毒株与野毒株的巢式PCR检测方法。建立的PCR快速检测方法能分别对PEDV疫苗毒株和野毒株扩增出特异性片段,片段大小分别为774 bp、150bp。该方法对传染性胃肠炎病毒(TGEV)、轮状病毒(Po RV)、猪瘟病毒(HCV)、伪狂犬病病毒(PRV)则不能扩增出特异性片段。该方法具有快速、灵敏、特异、通用等特点,可用于实验室的快速诊断、分子流行病学的调查和野毒株的分离鉴定。 相似文献
5.
猪伪狂犬病流行状况和疫苗应用的研究进展 总被引：1，自引：0，他引：1
近年来,猪伪狂犬病在国内许多Bartha-K61疫苗免疫的猪场暴发,传播迅速,严重危害我国养猪业的发展,引起了广泛关注和研究。相关研究表明,引起该病大规模暴发的病原为发生变异的猪伪狂犬病病毒(PRV),多数猪场的PRV野毒株感染普遍存在,因此,有必要对新型伪狂犬病病毒变异株的抗原性、致病性和分子特征及其疫苗的研制等方面进行研究。针对我国猪伪狂犬病的流行和疫苗应用的研究进展进行阐述,以便为研制新型疫苗及猪伪狂犬病的防控提供参考。 相似文献
6.
为了解狂犬病口服疫苗SRV9毒株的基因序列与生物学特性的关系,并就其主要抗原位点与国内外现用狂犬病疫苗生产毒株进行比较,明确其作为口服疫苗株的分子基础,本试验通过RT-PCR方法对狂犬病口服疫苗SRV9毒株的N、P、M、G、L基因分别进行克隆,并分别连接于pMD19-T载体,经酶切、测序鉴定后,用DNAStar软件对全基因序列进行分析,并与11株目前生产用狂犬病疫苗株进行基因序列比对分析和主要抗原位点的比较.狂犬病口服疫苗SRV9毒株N、P、M、G、L基因序列与其他毒株的序列同源性为81.8%~100.0%,由全基因组进化树可知,SRV9毒株与所有疫苗株在同一个大的分支内,均属于基因Ⅰ型,其中狂犬病口服疫苗SRV9毒株与ERA、SAD B19、SAG-2等口服疫苗株的进化距离最近,而与疫苗生产毒株aG、RC-HL 之间的进化距离则较远.狂犬病口服疫苗SRV9毒株与各疫苗株的糖蛋白不同结构区的氨基酸同源性分析表明,狂犬病口服疫苗SRV9毒株与SAD B19、SAG-2、ERA口服疫苗株的膜外区、跨膜区和膜内区的同源性最高.狂犬病口服疫苗SRV9毒株的基因组结构和抗原基因位点特征均与目前生产用口服疫苗株相似,这为今后狂犬病口服疫苗的研制和通过分子生物学技术构建基因重组弱毒疫苗株的研究提供了试验依据. 相似文献
7.
8.
两株狂犬病病毒强毒株糖蛋白基因的克隆及潜在抗原表位分析 总被引：2，自引：2，他引：2
通过RT-PCR分别获得了狂犬病病毒强毒CVS株、DRV82株糖蛋白基因,进行克隆及测序,并推导出氨基酸序列,与犬用疫苗弱毒株ERA、SRV9、犬源性街毒株CGX及人用疫苗株PG的糖蛋白序列进行比较。结果表明,以上狂犬病病毒毒株间的核苷酸同源性为83.1%～99.2%,氨基酸序列同源性为87.0%～98.5%。经Jameson-Wolf抗原表位优势图分析,CVS株与其他各株相比发现在304位、372位抗原表位优势升高;而DRV82株与其它各株差异不明显。抗原优势变化可能导致狂犬病病毒糖蛋白出现新的潜在抗原位点,为下一步构建不同毒株的狂犬病病毒糖蛋白重组疫苗奠定了基础。 相似文献
9.
狂犬病(Rabies)是一种由狂犬病病毒(RabiesVirus熏RV)引起的重要人畜共患传染病,一旦发病100%死亡,目前尚无有效的治疗方法,注射疫苗能有效预防狂犬病的发生。目前人用狂犬病疫苗主要是细胞培养疫苗,兽用疫苗主要是减毒活疫苗。人用狂犬病疫苗在细胞培养中增殖速度慢、滴度不高,要获得高效价的疫苗通常要经过纯化、浓缩。由于价格和产量的限制,主要用于暴露后免疫,兽用疫苗为减毒活疫苗,在注射后存在着发生狂犬病的潜在危险,因此,急需研制一种不含完整病毒颗粒、免疫原性好的疫苗。基因工程疫苗、合成肽、抗独特型抗体疫苗及基因疫苗正在… 相似文献
10.
应用病毒感染的鸡胚材料免疫新西兰兔的方法制备抗鸡传染性支气管炎病毒(IBV)单因子血清,然后在鸡胚气管环培养(Tracheal organ cultures,TOC)上对广西分离的7个IBV代表性毒株和3个常用疫苗株进行交叉病毒中和试验。结果显示,10个毒株被分为6个血清型。根据试验所得的R值,应用聚类分析法分析了各血清型毒株之间的亲缘关系,显示目前在广西流行的IBV野毒株之间以及其与疫苗株间的抗原性存在很大程度的差异,分属不同的血清型。同时还对IBV基因分型和血清分型之间的关系进行了探讨。 相似文献
11.
本研究通过神经瘤细胞（NA）培养CVS-11株狂犬病病毒,并测定不同批次的病毒毒价,为优化狂犬病疫苗的生产工艺提供数据支持,具有实际意义。病毒培养和检测结果表明,第1次和第2次收获的病毒液病毒含量较高,在107.0FFU/0.1 mL以上,毒力为106.4～107.0LD50/0.03 mL;而第3次收获的病毒含量则较低,只有106.0FFU/0.1 mL左右,毒力为105.0～105.3LD50/0.03 mL。第1次和第2次收获的病毒液可用于制备狂犬疫苗,第3次收获的病毒液因毒价较低不适于制备狂犬疫苗。 相似文献
12.
为快速检测犬狂犬病毒IgG抗体,应用狂犬病毒G蛋白作为捕获抗原,鼠抗狂犬病毒G蛋白单克隆抗体和羊抗犬IgG分别作为胶体金标记物和诊断抗体,羊抗鼠IgG作为质控线,制备胶体金免疫层析抗体检测试纸。该试纸卡具有良好的特异性、敏感性、重复性和稳定性,与快速荧光灶抑制实验检测值对比总符合率为82.1%。研究显示,本试纸卡能够快速、准确检测犬狂犬病毒IgG抗体,可为临床诊断和宠物犬狂犬疫苗免疫效果的评价提供参考。 相似文献
13.
James C. C. Chang 《Canadian journal of veterinary research》1965,29(2):38-41
Rabies virus and canine distemper virus were grown simultaneously, and possibly symbiotically, in the same chick embryos. There seemed to be no adverse effect on either virus when cultured in such manner.
Bivalent vaccines for rabies and canine distemper were produced. The potencies and the virus titers of such vaccines were comparable to those of rabies vaccine and canine distemper vaccine produced separately.
相似文献14.
A Brun G Chappuis P Precausta J P Soulebot J Terré 《Comparative immunology, microbiology and infectious diseases》1979,1(3):193-196
In a previous paper [3], we demonstrated that it was possible to vaccinate cats with a combined vaccine against Panleucopenia and Rabies.The purpose of this paper is to sum up the tests for safety and potency, carried out in cats vaccinated with a new combined vaccine against Panleucopenia and Rabies. This vaccine is different from that mentioned in the previous paper. The new Rabies vaccine is a vaccine adjuvanted by aluminium hydroxide.First of all, we shall examine the means and methods implemented and then, present the comparative results obtained with the two types of Rabies vaccine (whether adjuvanted or not) combined with the Panleucopenia live vaccine. 相似文献
15.
In ovo vaccination of specific-pathogen-free chickens with vaccines containing multiple agents. 总被引：2，自引：0，他引：2
We used in ovo technology to protect chickens against multiple diseases by inoculating vaccines containing mixtures of live viral agents. A single in ovo injection of a vaccine containing serotypes 1, 2, and 3 of Marek's disease virus (MDV), a vaccine strain of serotype 1 infectious bursal disease virus (IBDV), and recombinant fowl pox vaccine with HN and F genes of Newcastle disease virus (rFP-NDV) induced protection against virulent MDV, IBDV, Newcastle disease virus, and fowl poxvirus. The multiple-agent vaccine induced specific antibodies against the viral agents present in the mixture and did not adversely affect the survival of hatched chickens. Inoculation of a vaccine containing serotypes 1, 2, and 3 of MDV and IBDV did not affect hatchability of eggs, although the addition of rFP-NDV to the mixture reduced hatchability by 23%-26%. In ovo vaccination with a vaccine containing MDV and IBDV vaccine viruses did not exacerbate the inhibitory effect of individual viral agents on humoral and cellular immune competence. 相似文献
16.
Hermann JR Fry AM Siev D Slate D Lewis C Gatewood DM 《Canadian journal of veterinary research》2011,75(4):278-284
Rabies is an incurable zoonotic disease caused by rabies virus, a member of the rhabdovirus family. It is transmitted through the bite of an infected animal. Control methods, including oral rabies vaccination (ORV) programs, have led to a reduction in the spread and prevalence of the disease in wildlife. This study evaluated the stability of RABORAL, a recombinant vaccinia virus vaccine that is used in oral rabies vaccination programs. The vaccine was studied in various field microenvironments in order to describe its viability and facilitate effective baiting strategies. Field microenvironments influenced the stability of this vaccine in this study. This study emphasizes the importance of understanding how vaccines perform under varying field conditions in order to plan effective baiting strategies. 相似文献
17.
Occurrence and significance of infectious bronchitis virus variant strains in egg and broiler production in the Netherlands 总被引：2，自引：0，他引：2
Despite vaccination against Infectious bronchitis virus (IBV) with the Massachusetts type vaccine viruses H120 and H52 in the Netherlands, an increasing number of properly vaccinated flocks have suffered from the disease since 1978. In the years 1978-1982, the virus was isolated from 162 IBV suspected flocks. Cross-virus-neutralization tests showed that the majority (67 per cent) of these isolates belonged to serotypes other than the Massachusetts type, the Connecticut-, Florida-, Iowa 97-, Iowa 609- and JMK serotype. The majority of these Dutch isolates could be divided into 4 serogroups, called D207, D212, D3128 and D3896. Only a few isolates were not related to these serotypes. A survey of 328 flocks for antibody against these serotypes demonstrated that antibody against one or more of these novel serotypes were present in most of the flocks. Experiments demonstrated that vaccination with the H120 vaccine virus was not able to protect chickens against the adverse effects of a challenge with the novel serotypes. 相似文献
18.
为了建立狂犬病毒磷蛋白(phosphoprotein,P)的体外表达系统,本研究将RT-PCR扩增的狂犬病病毒ERA株P蛋白基因克隆于杆状病毒转移载体pFastBacHTA,构建重组质粒pFastBacHTA-P,并转染昆虫细胞Sf9包装形成重组杆状病毒。SDS-PAGE分析显示重组质粒pFastBacHTA-P转染的Sf9细胞中出现了分子量约为42 kDa的蛋白条带,Western blot证实分子量约为42 kDa的蛋白能与抗His的单克隆抗体发生特异性反应,间接免疫荧光(indirect immunofluorescence assay,IFA)分析进一步显示Sf9细胞表达的P蛋白与抗P蛋白单克隆抗体能特异性结合。这些实验证明,狂犬病病毒P蛋白不仅在Sf9细胞中获得表达,而且具有良好的免疫反应性。狂犬病病毒P蛋白杆状病毒表达体系的建立,为蛋白结构的解析和诊断试剂的研制奠定了基础。 相似文献
19.
Rabies is a neglected disease with an estimated annual mortality of 55,000 human deaths, affecting mainly low-income countries. Over 95% of these cases result from virus transmission through the bite of infected dogs and for this reason there is a real need for a cheap and effective rabies veterinary vaccine to be used in mass vaccination campaigns. In this work, we describe the establishment of a simple platform for the production of a virus-like particles based rabies vaccine using mammalian cells and roller bottles as culture system. Adherent cells were cultured during more than 15 days and VLPs were continuously produced and secreted to the culture supernatant. Immunogenicity and protective efficacy of VLPs were tested through rabies virus neutralizing antibody test and NIH potency test. These viral particles induced high titer of long lasting neutralizing antibodies and protected mice against active virus challenge. Therefore, this development represents a promising platform for the production of a new generation and virus-free rabies vaccine candidate for veterinary applications. 相似文献